uacc 3199 Search Results


93
ATCC uacc3199
BRCA1 CpG hypermethylation associates with constitutively active AHR in triple negative breast cancers (TNBC) cells. ( A ) Representative Western blot images comparing immunocomplexes of AHR and internal standard glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in HCC38 and <t>UACC3199</t> cells. ( B ) Data from methylation-specific PCR (MSP) comparing BRCA1 and ESR1 CpG methylation in HCC38 and MCF7 cells. ( C ) Bands represent immunocomplexes for BRCA1, estrogen receptor (ER)α, AHR, and internal standard GAPDH in MCF7 and HCC38 cells. ( D ) Comparison of AHR mRNA expression in HCC38 and MCF7 cells. ( E ) Expression of AHR targets CYP1A1 and CYP1B1 in HCC38 and MCF7 cells. ( F ) CYP1A1 and CYP1B1 expression in HCC38 cells treated with the AHR antagonist CH-223191. Bars represent sample means ± SEM from ≥3 biological replicates from individual experiments. VEH: vehicle-treated control. Asterisks indicate significant differences (*, p < 0.05; **, p < 0.01).
Uacc3199, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/uacc+3199/pmc06893467-56-1-10?v=ATCC
Average 93 stars, based on 1 article reviews
uacc3199 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


BRCA1 CpG hypermethylation associates with constitutively active AHR in triple negative breast cancers (TNBC) cells. ( A ) Representative Western blot images comparing immunocomplexes of AHR and internal standard glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in HCC38 and UACC3199 cells. ( B ) Data from methylation-specific PCR (MSP) comparing BRCA1 and ESR1 CpG methylation in HCC38 and MCF7 cells. ( C ) Bands represent immunocomplexes for BRCA1, estrogen receptor (ER)α, AHR, and internal standard GAPDH in MCF7 and HCC38 cells. ( D ) Comparison of AHR mRNA expression in HCC38 and MCF7 cells. ( E ) Expression of AHR targets CYP1A1 and CYP1B1 in HCC38 and MCF7 cells. ( F ) CYP1A1 and CYP1B1 expression in HCC38 cells treated with the AHR antagonist CH-223191. Bars represent sample means ± SEM from ≥3 biological replicates from individual experiments. VEH: vehicle-treated control. Asterisks indicate significant differences (*, p < 0.05; **, p < 0.01).

Journal: Nutrients

Article Title: Epigenetic Activation of BRCA1 by Genistein In Vivo and Triple Negative Breast Cancer Cells Linked to Antagonism toward Aryl Hydrocarbon Receptor

doi: 10.3390/nu11112559

Figure Lengend Snippet: BRCA1 CpG hypermethylation associates with constitutively active AHR in triple negative breast cancers (TNBC) cells. ( A ) Representative Western blot images comparing immunocomplexes of AHR and internal standard glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in HCC38 and UACC3199 cells. ( B ) Data from methylation-specific PCR (MSP) comparing BRCA1 and ESR1 CpG methylation in HCC38 and MCF7 cells. ( C ) Bands represent immunocomplexes for BRCA1, estrogen receptor (ER)α, AHR, and internal standard GAPDH in MCF7 and HCC38 cells. ( D ) Comparison of AHR mRNA expression in HCC38 and MCF7 cells. ( E ) Expression of AHR targets CYP1A1 and CYP1B1 in HCC38 and MCF7 cells. ( F ) CYP1A1 and CYP1B1 expression in HCC38 cells treated with the AHR antagonist CH-223191. Bars represent sample means ± SEM from ≥3 biological replicates from individual experiments. VEH: vehicle-treated control. Asterisks indicate significant differences (*, p < 0.05; **, p < 0.01).

Article Snippet: MCF7, UACC3199, and HCC38 BC cells were obtained from the American Type Culture Collection (ATCC).

Techniques: Western Blot, Methylation, CpG Methylation Assay, Comparison, Expressing, Control